Y-mAbs Therapeutics, Inc.
$1.7M 159 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pharmacosmos Therapeutics Inc.
Pharmacosmos Therapeutics Inc. reported $1,726,720.75 across General Payments, Research, and Ownership to 7,020 physicians and teaching hospitals across 7,110 transactions.
- $1.7M Above-median payer
- All-tracks total
- 7,110 Top quartile volume
- Transactions
- 7,020 Top quartile reach
- Recipients
- +$350.1K
- General Payments vs PY2023
Pharmacosmos Therapeutics Inc. reported $1,726,720.75 across all CMS Open Payments tracks (General + Research + Ownership) to 7,020 physicians and teaching hospitals in Program Year 2024 - ranking #486 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,445,949.85, averaging $245.97 per recipient.
How Pharmacosmos Therapeutics Inc.'s $1.7M all-tracks total breaks down
Pharmacosmos Therapeutics Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
50/100
Total payments
F
26/100
Transaction volume
D
62/100
Physician reach
D
63/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pharmacosmos-therapeutics-inc Pharmacosmos Therapeutics Inc.
$1.7M · #486/1,925 · 0.0% industry · PY2024
- TOT $1.7M
- RANK #486
- SHARE 0.0%
- TXN 7,110
- RCP 7,020
- CAT 4
- GEN $1.4M
- ΔGEN +$350.1K
- TOP1 9.9%
- PY 2024
Volume peers
Nearest volume peer: Y-mAbs Therapeutics, Inc. ($1.7M)
Pharmacosmos Therapeutics Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pharmacosmos Therapeutics Inc.'s CMS-reported General Payments increased by $350.1K (+31.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PHARMACOSMOS THERAPEUTICS INC.PY2023: PHARMACOSMOS THERAPEUTICS INC.PY2024: Pharmacosmos Therapeutics Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,095,836.22
- PY2024
- $1,445,949.85
What the Data Shows for Pharmacosmos Therapeutics Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Pharmacosmos Therapeutics Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $746.1K, accounting for 51.6% of this company's General Payments and 169 transactions.
General Payment Breakdown by Type
"Honoraria" leads Pharmacosmos Therapeutics Inc.'s 4-category general-payment breakdown at $746.1K, 51.6% of the reported total.
Pharmacosmos Therapeutics Inc. reports 4 general-payment categories - the top three are Honoraria (51.6%), Travel and Lodging (19.9%), and Consulting Fee (14.9%). The remaining 1 category make up 13.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Pharmacosmos Therapeutics Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $746.1K | 169 | 51.6% |
| Travel and Lodging | $287.2K | 407 | 19.9% |
| Consulting Fee | $215.0K | 30 | 14.9% |
| Food and Beverage | $197.6K | 6,414 | 13.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $452,420.85 (31.3%) of $1,445,949.85 in this company's General Payments records across 4,138 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pharmacosmos Therapeutics Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Aryeh Shander
$142,933.50 across 15 reported transactions
- 2
Myles Wolf
$136,015.91 across 19 reported transactions
- 3
Suresh Ratnam
$62,918.96 across 38 reported transactions
- 4
Christopher Chen
$57,920.56 across 103 reported transactions
- 5
Hassan Kaleem
$52,631.92 across 77 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pharmacosmos Therapeutics Inc. ranks #486 of 1,925 by total payments (top 25% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,448 of 1,838 by HHI (bottom 21% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Ucb SA : $1.1M total payments, HHI 317
- PolyNovo North America LLC : $827.7K total payments, HHI 315
- Piedmont Plus Innovation : $24.7K total payments, HHI 314
- Goode Surgical Inc : $24.0K total payments, HHI 314
- Vision Quest Industries Inc. : $2.1K total payments, HHI 314
- United Orthopedics LLC : $47.9K total payments, HHI 313
- Pharmacosmos Therapeutics Inc. (this company) : $1.4M total payments, HHI 311
- Carl Zeiss Meditec Digital Innovations LLC : $167.7K total payments, HHI 311
- Meisinger USA, LLC : $46.0K total payments, HHI 310
- MedShape, Inc. : $1.2M total payments, HHI 309
- Garrison Dental Solutions : $162.0K total payments, HHI 308
- Ossio Inc : $357.9K total payments, HHI 307
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pharmacosmos Therapeutics Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pharmacosmos Therapeutics Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pharmacosmos Therapeutics Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Dompe US, Inc.
$1.7M 11,308 recipients
Compare payment profiles
Esperion Therapeutics, Inc.
$1.7M 27,251 recipients
Compare payment profiles
bioMerieux Inc
$1.7M 600 recipients
Compare payment profiles
Radiometer America, Inc
$1.7M 84 recipients
Compare payment profiles
Medivation LLC.
$1.7M 3 recipients
Compare payment profiles
Put this to use
Pharmacosmos Therapeutics Inc. ranks #486 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Pharmacosmos Therapeutics Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Pharmacosmos Therapeutics Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.